S
Stephen D. Smith
Researcher at Fred Hutchinson Cancer Research Center
Publications - 103
Citations - 2137
Stephen D. Smith is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Mantle cell lymphoma & Rituximab. The author has an hindex of 18, co-authored 103 publications receiving 1394 citations. Previous affiliations of Stephen D. Smith include University of Washington & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
Michael Wang,Simon Rule,Pier Luigi Zinzani,Andre Goy,Olivier Casasnovas,Stephen D. Smith,Gandhi Damaj,Jeanette K. Doorduijn,Thierry Lamy,Franck Morschhauser,Carlos Panizo,Bijal D. Shah,Andrew Davies,Andrew Davies,Richard Eek,Jehan Dupuis,Eric D. Jacobsen,Arnon P. Kater,Steven Le Gouill,Lucie Oberic,Taduesz Robak,Todd Covey,Richa Dua,Ahmed Hamdy,Xin Huang,Raquel Izumi,Priti Patel,Wayne Rothbaum,J. Greg Slatter,Wojciech Jurczak +29 more
TL;DR: Oral acalabrutinib treatment provided a high rate of durable responses and a favourable safety profile in patients with relapsed or refractory mantle cell lymphoma, and suggest an important role for acAlabrUTinib in the treatment of this disease population.
Journal ArticleDOI
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity
Caron A. Jacobson,Bradley D. Hunter,Robert A. Redd,Scott J. Rodig,Pei Hsuan Chen,Kyle Wright,Mikel Lipschitz,Jerome Ritz,Yusuke Kamihara,Philippe Armand,Sarah Nikiforow,Michael Rogalski,Joseph E. Maakaron,Samantha Jaglowski,Marcela V. Maus,Yi-Bin Chen,Jeremy S. Abramson,Justin Kline,Elizabeth Budde,Alex F. Herrera,Matthew Mei,Jonathon B. Cohen,Stephen D. Smith,David G. Maloney,Ajay K. Gopal,Matthew J. Frigault,Utkarsh Acharya,Utkarsh Acharya +27 more
TL;DR: Axi-cel yields similar rates of overall response and toxicity in commercial and trial settings, although CR rates and DOR were more favorable in patients eligible for ZUMA-1.
Journal ArticleDOI
Derivatives and Corporate Risk Management: Participation and Volume Decisions in the Insurance Industry
TL;DR: In this paper, the authors explore the factors that influence the use of financial derivatives in the U.S. insurance industry and develop a set of hypotheses regarding the hedging behavior of insurers and perform tests on a sample of life and property-liability insurers.
Journal ArticleDOI
Derivatives and corporate risk management: participation and volume decisions in the insurance industry
TL;DR: This article analyzed the derivatives holdings of U.S. insurers to empirically investigate the general hypotheses developed in the financial literature to explain why widely held, value-maximizing firms engage in risk management.
Journal ArticleDOI
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
Andrew D. Zelenetz,Leo I. Gordon,Jeremy S. Abramson,Ranjana H. Advani,Nancy L. Bartlett,Paolo Caimi,Julie E. Chang,Julio C. Chavez,Beth Christian,Luis Fayad,Martha Glenn,Thomas M. Habermann,Nancy L. Harris,Francisco J. Hernandez-Ilizaliturri,Mark S. Kaminski,Chris R. Kelsey,Nadia Khan,Susan Krivacic,Ann S. LaCasce,Amitkumar Mehta,Auayporn Nademanee,Rachel Rabinovitch,Nishitha Reddy,Erin Reid,Kenneth B. Roberts,Stephen D. Smith,Erin D Snyder,Lode J. Swinnen,Julie M. Vose,Mary A. Dwyer,Hema Sundar +30 more
TL;DR: The NCCN Guidelines Insights as mentioned in this paper highlight important updates for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.